ORION CORPORATION STOCK EXCHANGE RELEASE 13 JUNE 2014 at 9.30
200,000 Orion A-shares converted into B-shares
In accordance with Section 3 of the Articles of Association of Orion
Corporation, 200,000 A-shares have been converted into 200,000 B-shares. The
conversion has been entered into the Trade Register on 13 June 2014.
The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 41,522,816 A-shares and 99,735,012 B-shares.
Olli Huotari Jari Karlson
SVP, Corporate Functions CFO
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.